LupusTrials.org First posted November 30, 2021, Updated May 20, 2022; Recruiting This Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of anifrolumab versus placebo as added to SOC (consisting of MMF and glucocorticoids) in adults with active proliferative Class III or Class IV LN (both with or without concomitant Class …
Archives: Trials
ELEVATE – (Empower Lupus Erythematosus Patients Via Allowing RemoTe Evaluation) (ELEVATE)
First posted April 27, 2022, Updated May 5, 2022; Recruiting CATEGORIES: Lupus The purpose of this large observational trial is to explore the potential for use of DxTerity’s AIP IFN-1 test as personalized guided care and monitoring module in patients with Systemic lupus erythematosus(SLE) using consented patient health information To Learn More Contact Deepti Sood Gupta …
PRV-3279-2a Trial in Systemic Lupus (PREVAIL-2)
First posted October, 2021, Updated January, 2022; Recruiting CATEGORIES: Lupus The purpose of this Phase 2a PREVAIL-2 trial is to assess the safety and potential efficacy of PRV-3279 in flare prevention in systemic lupus erythematosus (SLE) patients with active disease after amelioration induced by corticosteroid treatment. To Learn More Contact Clinical Operations at 857-675-1664 or …
A novel Phase 2 double-blind, randomized, controlled clinical trial to evaluate the efficacy of centrally acting, non-toxic ACE inhibition in cognitive impairment associated with SLE
First posted July, 2020, Updated November, 2021; Recruiting CATEGORIES: CNS Lupus This research study is being done to test the effects of centrally-acting ACE inhibitor, named lisinopril, on resting metabolism in the brain and on cognitive function. The investigators will see if Lisinopril will decrease resting metabolism in the brain and improve cognitive function (memory …
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
First posted September, 2020, Updated September, 2021; Recruiting CATEGORIES: Lupus Nephritis The objectives of this Phase 2, Double-Blind, Randomized, Placebo-Controlled Study is to evaluate the efficacy and safety of ravulizumab in adult participants With proliferative lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN) To Learn More Contact Contact: Alexion Pharmaceuticals, Inc.at 855-752-2356 or clinicaltrials@alexion.com ClinicalTrials.gov identifier: …
A Study of Guselkumab in Participants With Active Lupus Nephritis (ORCHID-LN)
First posted May, 2020, Updated August, 2021; Recruiting CATEGORIES: Lupus Nephritis The purpose of this Phase 2 study is to evaluate the efficacy of guselkumab in participants with active lupus nephritis (LN). This study is being offered at 8 LuCIN sites – institutions that are members of the Lupus Clinical Investigators Network managed by Lupus …
Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus
First filed December 23, 2020, Updated September, 2021; Recruiting CATEGORIES: General SLE The purpose of this Phase 2 study is to evaluate the efficacy and safety of efavaleukin alfa in subjects with active SLE. This study is being offered at 20 LuCIN sites – institutions that are members of the Lupus Clinical Investigators Network managed …
A Phase 2 of VIB7734 for the Treatment of Moderate to Severely Active SLE (RECAST SLE)
First filed June, 2021, Updated June, 2021; Recruiting CATEGORIES: General SLE The purpose of this Phase 2 randomized, double-blind, placebo-controlled study is to study the safety and efficacy of VIB7734 for the treatment of moderate to severely active Systemic Lupus Erythematosus in approximately 195 participants. This study is being offered at 7 LuCIN sites – …
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
CATEGORIES: SLE This randomized, multi-site, adaptive, open-label clinical trial will compare the immune response to different COVID-19 vaccine booster doses in participants with autoimmune disease requiring immunosuppressive medications. To Learn More Contact Judith A. James, MD, PhD, Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation Meggan C. Mackay, MD, MS, Center of Autoimmune Musculoskeletal …
Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis (SELUNE)
The purpose of this trial is to evaluate the efficacy and safety of subcutaneous secukinumab 300 mg compared to placebo, in combination with standard of care therapy (SoC), in subjects with active lupus nephritis (ISN/RPS Class III or IV, with or without co-existing class V features). To Learn More Contact Novartis Pharmaceuticals at 1-888-669-6682 or …